Search

Displaying results 9381 - 9390 of 9679 in total
  1. Drug

    Leuvectin

    go.drugbank.com/drugs/DB17303
    Investigational

    Leuvectin (formerly known as VCL-1102) is a component of gene therapy along with cationic lipid 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide/dioleyl-phosphatidyl-ethanolamine (DMRIE

  2. Drug

    CAR BCMA-CS1

    go.drugbank.com/drugs/DB17313
    Experimental

    CAR BCMA-CS1 is a lentiviral transfected chimeric antigen receptor (CAR) T-cell therapy modified to target B-cell maturation antigen and CS1.

  3. Drug

    TPIV 200

    go.drugbank.com/drugs/DB17318
    Investigational

    TPIV 200 is a vaccine consisting of proteins from the folate receptor alpha mixed with Granulocyte-macrophage colony-stimulating factor (GM-CSF).

  4. Drug

    ICG-136

    go.drugbank.com/drugs/DB17343
    Experimental

    ICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics. It was investigated for the treatment of acute myeloid leukemia.

  5. Drug

    Obecabtagene autoleucel

    go.drugbank.com/drugs/DB17362
    ApprovedInvestigational

    Obecabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with a fast off-rate binding profile for CD19.

    Synonyms: A CHIMERIC ANTIGEN RECEPTOR (CAR) CONSISTING O, AUTOLOGOUS CD4+ AND CD8+ T CELLS, ENRICHED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) OBTAINED BY APHERESIS TRANSDUCED EX VIVO WITH A NON-REPLICATING, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING
  6. Drug

    Saposin C

    go.drugbank.com/drugs/DB17380
    Investigational

    Saposin C is a lysosomal protein. Recombinant, non-glycosylated Saposin C is an active ingredient of BXQ-350, which is a novel, investigational anti-neoplastic therapy. … BXQ-350 consists of Saposin C and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes.

  7. Drug

    AUM-601

    go.drugbank.com/drugs/DB17382
    Experimental

    AUM-601 is a highly selective pan-TRK(tropomyosin receptor kinase). It is currently being investigated in clinical trials for the treatment of cancer.

  8. Drug

    Gemogenovatucel-T

    go.drugbank.com/drugs/DB17412
    Investigational

    Gemogenovatucel-T is a bi-shRNA furin/Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented autologous tumour cell vaccine. … Furin is a convertase involved in the activation of TGFβ-1 and TGFβ-2.[A255163] Gemogenovatucel-T is being investigated in the treatment of various cancers.

  9. Drug

    Trastuzumab botidotin

    go.drugbank.com/drugs/DB17413
    Experimental

    A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (trastuzumab) via a stable protease-cleavable

  10. Drug

    BS-001

    go.drugbank.com/drugs/DB17415
    Investigational

    BS-001 is a recombinant oncolytic herpes simplex virus type II (OH2) therapeutic injection (Vero cell) for human use (rHSV2hGM-CSF).